Gabexate Mesylate - CAS 39492-01-8
Catalog number:
39492-01-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C16H23N3O4
Molecular Weight:
321.375
COA:
Inquire
Targets:
Others
Description:
Gabexate mesylate is a serine protease inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation, and as a regional anticoagulant for haemodialysis.
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥98%
Appearance:
White solid
Synonyms:
GABEXATE;GabexateMesylateBase;[N'-[5-(4-ethoxycarbonylphenoxy)carbonylpentyl]carbamimidoyl]azanium methanesulfonate;4-[(6-Guanidinohexanoyl)oxy]benzoic acid ethyl ester;4-[[6-[[Amino(imino)methyl]amino]-1-oxohexyl]oxy]benzoic acid ethyl ester
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Serine Protease inhibitor
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
Melting Point:
89-93 °C
Density:
1.2g/cm3
InChIKey:
DNTNDFLIKUKKOC-UHFFFAOYSA-N
InChI:
1S/C16H23N3O4.CH4O3S/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18;1-5(2,3)4/h7-10H,2-6,11H2,1H3,(H4,17,18,19);1H3,(H,2,3,4)
Canonical SMILES:
CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N.CS(=O)(=O)O
1.The efficacy of the administration of recombinant human soluble thrombomodulin in patients with DIC.
Aota T1, Wada H2, Yamashita Y1, Matsumoto T3, Ohishi K3, Suzuki K4, Imai H4, Usui M5, Isaji S5, Katayama N1. Int J Hematol. 2016 Feb;103(2):173-9. doi: 10.1007/s12185-015-1899-5. Epub 2015 Nov 21.
Efficacy of recombinant human soluble thrombomodulin (rhTM), which is frequently used to treat patients with disseminated intravascular coagulation (DIC), was compared with that of gabexate mesilate (GM), which was previously used routinely in the treatment of DIC patients in Japan. Although there was no significant difference in the resolution rates of the patients who were treated with rhTM and GM, the results of our analysis revealed that the mortality rate was significantly higher among infectious disease patients treated with GM than in those treated with rhTM. Levels of fibrinogen and fibrin degradation products (FDP), antithrombin (AT) activity, and thrombin AT complex (TAT) were significantly lower in the DIC patients with infectious diseases, while fibrinogen levels were high. FDP level, D-dimer, platelet count, PT ratio, and DIC score all showed significant improvement following rhTM treatment. There were no significant difference between survivors and non-survivors in terms of DIC score, FDP level, platelet count, AT activity, or in TAT, SF and PPIC levels before rhTM treatment.
2.Targeting mast cells in gastric cancer with special reference to bone metastases.
Leporini C1, Ammendola M1, Marech I1, Sammarco G1, Sacco R1, Gadaleta CD1, Oakley C1, Russo E1, De Sarro G1, Ranieri G1. World J Gastroenterol. 2015 Oct 7;21(37):10493-501. doi: 10.3748/wjg.v21.i37.10493.
Bone metastases from gastric cancer (GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis. Both primary GC and its metastatic progression rely on angiogenesis. Several lines of evidence from GC patients strongly support the involvement of mast cells (MCs) positive to tryptase (MCPT) in primary gastric tumor angiogenesis. Recently, we analyzed infiltrating MCs and neovascularization in bone tissue metastases from primary GC patients, and observed a significant correlation between infiltrating MCPT and angiogenesis. Such a finding suggested the involvement of peritumoral MCPT by infiltrating surrounding tumor cells, and in bone metastasis angiogenesis from primary GC. Thus, an MCPT-stimulated angiogenic process could support the development of metastases in bone tissue. From this perspective, we aim to review the hypothetical involvement of tumor-infiltrating, peritumoral MCPT in angiogenesis-mediated GC cell growth in the bone microenvironment and in tumor-induced osteoclastic bone resorption.
3.Safety and efficacy of early drain removal and triple-drug therapy to prevent pancreatic fistula after distal pancreatectomy.
Adachi T1, Kuroki T2, Kitasato A2, Hirabaru M2, Matsushima H2, Soyama A2, Hidaka M2, Takatsuki M2, Eguchi S2. Pancreatology. 2015 Jul-Aug;15(4):411-6. doi: 10.1016/j.pan.2015.05.468. Epub 2015 May 29.
OBJECTIVE: Prior studies suggested that early drain removal prevented the development of pancreatic fistula (PF) after pancreaticoduodenectomy (PD), but there has been no corresponding prospective trial for distal pancreatectomy (DP). The purpose of this study was to determine the safety and efficacy of early drain removal and triple-drug therapy (TDT) with gabexate mesilate, octreotide and carbapenem antibiotics to prevent PF after DP in patients at high-risk of developing PF.
4.[Anti DIC therapy].
Yahata M, Sakamoto Y. Nihon Rinsho. 2016 Feb;74(2):257-61.
A variety of disorders erratically activate coagulation cascades. The disseminated intravascular coagulation (DIC) is caused by unbalanced activation between coagulation and fibrinolysis. Some of auxiliary treatments for DIC on top of main therapy against causative disease are beneficial in terms of better outcome. The anticoagulation therapy is indicated when an activation of coagulation dominates in DIC caused by sepsis. Whereas in DIC associated with trauma, since balance between coagulation and fibrinolysis collapses drastically in a short period, both anticoagulantion therapy and antifibrinolytic therapy can be utilized depending on clinical conditions. There are quite a few of anti DIC agents in Japan. It is imperative to choose appropriate agents to treat DIC taking their pharmacological properties into account.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


BMS-394136
(CAS: 343246-73-1)

BMS-394136 is a synthetic bio-active chemical.

ARV-825
(CAS: 1818885-28-7)

ARV-825, a BRD4 inhibitor, has extensive anti-AML activity and modulates tumor microenvironment and metabolism to overcome stromamediated drug resistance. DC50...

CAS 1016535-83-3 MDK35833

MDK35833
(CAS: 1016535-83-3)

MDK35833, also called as Oct3/4-inducer-1, is a potent Oct3/4-inducer, which enhances its transcriptional activity in diverse human somatic cells, implying the ...

PD-116152
(CAS: 101708-64-9)

PD-116152 is a novel and highly substituted phenazine. It has antitumor activity. It was isolated from the culture broth of a Streptomyces sp.

CAS 6747-15-5 D,L-3-Indolylglycine

D,L-3-Indolylglycine
(CAS: 6747-15-5)

D, L-3-Indolylglycine, similar to Tryptophan, is an unnatural amino acid.

CAS 41451-75-6 Bruceantin

Bruceantin
(CAS: 41451-75-6)

Bruceantin is first isolated from Brucea antidysenterica, a tree used in Ethiopia for the treatment of cancer, and activity was observed against B16 melanoma, c...

AM-206
(CAS: 1219935-54-2)

AM-206 is a bio-active chemical but no detailed data has been published yet.

CAS 3819-00-9 Piperacetazine

Piperacetazine
(CAS: 3819-00-9)

Piperacetazine is an antipsychotic drug, most notably used for schizophrenia

CAS 35449-36-6 Gemcadiol

Gemcadiol
(CAS: 35449-36-6)

Gemcadiol is a new antilipemic drug with lipid-regulating properties.

CAS 472-61-7 Astaxanthin

Astaxanthin
(CAS: 472-61-7)

Carotenoid pigment found mostly in animal organisms, but also occuring in plants; thought to be the precursor of astacin. Astaxanthin is a carotenoid pigment fo...

CAS 2030-63-9 Clofazimine

Clofazimine
(CAS: 2030-63-9)

Clofazimine stimulates oxygen consumption and superoxide generation by neutrophils, Clofazimine also causes phospholipase A2 activation in neutrophils, resultin...

GYKI-23107 dihydrochloride
(CAS: 83843-39-4)

GYKI-23107 is an antiarrhythmic agent with local anaesthetic activity.

CAS 339-44-6 Glymidine

Glymidine
(CAS: 339-44-6)

Glycodiazine is a sulfapyrimidine derivative with antihyperglycemic activity used in biological activities to predict human intestinal absorption in drug discov...

CVT10216
(CAS: 1005334-57-5)

CVT10216 is a potent and selective, reversible inhibitor of aldehyde dehydrogenase 2 (ALDH2) with IC50 value of 29nM, thereby inhibiting dopamine synthesis. It ...

CAS 73-48-3 rac Bendroflumethiazide

rac Bendroflumethiazide
(CAS: 73-48-3)

Bendroflumethiazide is a thiazide diuretic as a Na++Cl- symport inhibitor. Bendroflumethiazide can be used in the treatment of mild heart failure although loop ...

CAS 83657-24-3 Diniconazole

Diniconazole
(CAS: 83657-24-3)

Diniconazol is a chemical compound belongs to chlorine group of conazole. It is used as fungicide. It inhibited lanosterol 14 alpha-demethylation catalyzed by a...

UK 34787
(CAS: 72818-36-1)

UK 34787 is a thromboxane inhibitor,but no detailed information has been published yet.

CAS 96020-91-6 Eflornithine hydrochloride, hydrate

Eflornithine hydrochloride, hydrate
(CAS: 96020-91-6)

Eflornithine hydrochloride, hydrate is a drug found to be effective in the treatment of facial hirsutism. It is a "suicide inhibitor," irreversibly binding to O...

CAS 86764-11-6 Isoastragaloside II

Isoastragaloside II
(CAS: 86764-11-6)

Isoastragaloside II is an astragaloside, which is isolated from the hairy root culture of Astragalus membranaceus.

NK-1145 Hydrochloride
(CAS: 16487-37-9)

The hydrochloride salt form of NK-1145, an azabicyclo derivative, has been found to be a parasympatholytic drug that could induce stimulation and excitement.

Chemical Structure

CAS 39492-01-8 Gabexate Mesylate

Quick Inquiry

Verification code

Featured Items